Advertisement
UK markets closed
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     
  • AIM

    764.38
    -0.09 (-0.01%)
     
  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     
  • GBP/USD

    1.2646
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    48,711.84
    +521.97 (+1.08%)
     
  • CMC Crypto 200

    1,278.03
    -5.80 (-0.45%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • DOW

    39,118.86
    -45.20 (-0.12%)
     
  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     
  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     
  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     
  • DAX

    18,235.45
    +24.90 (+0.14%)
     
  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     

Insider Stock Buying Reaches US$751.8k On Vivani Medical

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Vivani Medical, Inc.'s (NASDAQ:VANI) case, it's fantastic news for shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Vivani Medical

Vivani Medical Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Chairman of the Board Gregg Williams bought US$135k worth of shares at a price of US$0.88 per share. Even though the purchase was made at a significantly lower price than the recent price (US$1.63), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

ADVERTISEMENT

Vivani Medical insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

Vivani Medical is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Does Vivani Medical Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Vivani Medical insiders own 34% of the company, worth about US$31m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Vivani Medical Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Vivani Medical shares in the last quarter. However, our analysis of transactions over the last year is heartening. Overall we don't see anything to make us think Vivani Medical insiders are doubting the company, and they do own shares. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Vivani Medical. Our analysis shows 6 warning signs for Vivani Medical (2 are potentially serious!) and we strongly recommend you look at these before investing.

Of course Vivani Medical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.